跳到主要內容

臺灣博碩士論文加值系統

(100.28.231.85) 您好!臺灣時間:2024/11/09 01:08
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果 :::

詳目顯示

: 
twitterline
研究生:蕭雅方
研究生(外文):Ya-Fang Shiau
論文名稱:缺血性中風或暫時性腦缺血病人預防再中風及死亡的抗血小板用藥之研討
論文名稱(外文):Secondary Prevention of Stroke and Death by Antiplatelet Therapies in Patients with Ischemic Stroke or Transient Ischemic Attack
指導教授:胡朝榮胡朝榮引用關係
指導教授(外文):Chaur-Jong Hu
學位類別:碩士
校院名稱:臺北醫學大學
系所名稱:藥學研究所
學門:醫藥衛生學門
學類:藥學學類
論文種類:學術論文
論文出版年:2009
畢業學年度:97
語文別:英文
論文頁數:86
中文關鍵詞:缺血性中風暫時性腦缺血再中風台灣腦中風學會多醫院中風登錄計畫抗血小板藥物 (AspirinDipyridamoleAggrenox®Clopidogrel)
外文關鍵詞:Ischemic strokeTransient ischemic attackRecurrent strokeTaiwan Stroke RegistryAntiplatelet agents (AspirinDipyridamoleAggrenox®Clopidogrel)
相關次數:
  • 被引用被引用:0
  • 點閱點閱:358
  • 評分評分:
  • 下載下載:3
  • 收藏至我的研究室書目清單書目收藏:1
摘要
研究背景
缺血性中風或是暫時性腦缺血病人是再中風的高危險族群。用於預防再中風的第一線抗血小板藥物,包括Aspirin、Aspirin合併extended-release dipyridamole (ASA-ERDP)、以及Clopidogrel。根據過去研究結果顯示,價錢較昂貴的藥物如ASA-ERDP和Clopidogrel比Aspirin能更有效預防再中風。但是,大部分的研究並未針對這三種抗血小板藥物預防再中風或是其他缺血性事件的風險進行head-to-head的直接比較。本研究的目的為探討台灣缺血性中風或是暫時性腦缺血病人最有效預防再中風或死亡的抗血小板治療藥物。

研究方法
本回溯性研究所分析之病人資料取自「台灣腦中風學會多醫院中風登錄計畫」,利用其登錄資料來分析缺血性中風或是暫時性腦缺血病人中風後發生危險事件之風險。研究之病人為服用下列三種抗血小板藥物之一: (1) Aspirin (A組),(2) Aspirin併用Dipyridamole或是複方劑型Aggrenox® (A加D組),及 (3) Clopidogrel (C組)。本研究之Primary Outcomes為病人發生缺血性中風或是暫時性腦缺血後一個月內、三個月內及六個月內再中風或是死亡的事件。另外,本研究對缺血性中風五種TOAST (Trial of Org 10172 in Acute Stroke Treatment)各亞型、心房震顫病史及上消化道出血併發症的病人針對Primary Outcomes另做分組分析。本研究使用存活分析之Kaplan-Meier method及Cox proportional hazards regression model進行統計分析。

研究結果
本研究共收集10,792位病人,其中A組、A加D組及C組之病人數分別為7,377人、1,902人、1,513人。C組病人有心臟疾病或是中風病史各佔40%,明顯高於其他組約兩倍。中風後六個月內,共有251人發生再中風,包括2.20% A組病人、2.47% A加D組病人、及2.71% C組病人。校正病人基本特性後,三組病人再中風的風險比並沒有差異(p > 0.05)。中風後六個月內有368位病人死亡,包括2.91% A組病人、2.79% A加D組病人、及6.61% C組病人;其中,C組病人的死亡率相對較高(p < 0.001)。校正病人基本特性後(例如:年齡、心臟病史、過去曾發生中風),三組病人死亡的風險比並沒有差異(p > 0.05)。此外,缺血性中風五種TOAST各亞型、心房震顫病史的分組分析不論是A加D組或是C組,相較於A組,預防再中風或是死亡的風險並沒有差異(p > 0.05)。然而,上消化道出血併發症病人的分組分析中,顯示C組相較於A組在中風後一個月內死亡的風險較低 (p = 0.039)。而在A加D組和C組之間的再中風或死亡的分組比較,研究結果顯示兩組沒有統計上的差異(p > 0.05)。

研究結論
根據過去臨床報告顯示,病人發生缺血性中風後未使用抗血小板藥物,其半年內再中風的風險為7%。根據本研究結果,Aspirin、Aspirin合併Dipyridamole、以及Clopidogrel在降低台灣缺血性中風及暫時性腦缺血病人再中風或是死亡風險的效果是沒有差異的,約2.5%病人半年內發生再中風。基於本研究結果,建議臨床醫師應開立Aspirin為預防再中風的第一線抗血小板治療用藥,除非病人對Aspirin過敏或是無法耐受其副作用 (例如:上消化道出血)。而Aspirin的低藥價亦可以讓病人有較好的長期服藥習慣。病人如果本身有出血症狀且併用抗血小板藥物,有可能會造成較高的死亡率。因此,有出血症狀的缺血性中風病人應使用Clopidogrel作為預防再中風的首選用藥,避免使用含有Aspirin成分的藥物。
Abstract
Background
Patients survived from ischemic stroke or transient ischemic attack (TIA) are high risk population for recurrent stroke. Antiplatelet agents, such as aspirin, the combination of aspirin plus extended-release dipyridamole (ASA-ERDP) and clopidogrel, are the first-line antiplatelet therapies for prevention of recurrent stroke in patients with ischemic stroke or TIA. Based on previous reports, the more expensive agents such as ASA-ERDP and clopidogrel are more effective than aspirin alone for the secondary prevention of stroke. However, most of the previous clinical trials fail to compare head-to-head directly three antiplatelet agents for the risk of recurrent stroke or other ischemic events. The aim of the present study was to investigate which antiplatelet therapy is the most effective in reducing the risk of recurrent stroke or death for patients with ischemic stroke or TIA in Taiwan.

Method
In this retrospective study, the patients’ data were obtained from the databank of Taiwan Stroke Registry, for analyzing subsequent risks in patients suffering from prior ischemic stroke or TIA. Patients in this study were treated with one of the following antiplatelet therapies such as (1) aspirin alone (Group A), (2) either the combination of aspirin plus dipyridamole or Aggrenox® (Group A plus D), and (3) clopidogrel alone (Group C). The primary outcomes were recurrent stroke and death within one month, three months, and six months after the onset of ischemic stroke or TIA. The subgroup analyses were performed for the primary outcomes with the baseline features, including five TOAST (Trial of Org 10172 in Acute Stroke Treatment) subtypes of ischemic stroke, history of atrial fibrillation, and patients with upper gastrointestinal bleeding. The statistical methods of the Kaplan-Meier method and the Cox proportional hazards regression model were used to analyze the results.

Results
A total of 10,792 patients were collected in this study. The final patient numbers for each therapy groups of A, A plus D, and C were 7,377, 1,902, and 1,513 patients, respectively. The patients of group C were associated with history of heart disease (40%) or prior stroke (40%), all of which were greater than other two groups. A total of 251 patients suffered recurrent stroke during six months after prior ischemic stroke or TIA. About 2.20% of group A patients, 2.47% of group A plus D patients, and 2.71% of group C patients developed recurrent stroke within six months after ischemic stroke or TIA. After adjusting baseline characteristics, the hazard ratios for recurrent stroke among three treatment groups did not reach statistical significance
(p > 0.05). During the six-month period of follow-up, 368 patients died for unknown reason. The mortality rate of group A, group A plus D, and group C were 2.91%, 2.79%, and 6.61%, respectively. A significant two fold higher mortality rate was observed in group C (p < 0.001). After adjusting baseline features (e.g., age, heart disease, previous stroke), the hazard ratios for death among three treatment groups were not different significantly (p > 0.05). Subgroup analyses of five TOAST subtypes and the history of atrial fibrillation revealed that neither group A plus D treatment nor group C therapy produced a significant effect on the risk of recurrent stroke or death compared with group A (p > 0.05). However, a confirmatory finding was that patients with upper gastrointestinal bleeding in group C after receiving clopidogrel treatment had less risk of death than those in group A after receiving aspirin alone treatment within the first month after the onset of ischemic stroke or TIA (p = 0.039). Consistent with primary outcomes, subgroup analyses for recurrent stroke or death between group A plus D and group C also indicated that there were no statistically significant differences (p > 0.05).

Conclusion
Based on the previous clinical reports, approximately 7% ischemic stroke patients without antiplatelet therapies developed recurrent stroke within six months. In the present study, aspirin alone, the combination of aspirin plus dipyridamole, and clopidogrel alone were effective in the prevention of recurrent stroke or death in Taiwanese patients with ischemic stroke or TIA; patients who received antiplatelet treatments in this study decreased the risk of recurrent stroke to about 2.5%. With this evidence-based information in mind, aspirin monotherapy is recommended to be prescribed as the first-line antiplatelet therapy for secondary prevention of stroke unless patients are allergy to or intolerant of aspirin (e.g., upper gastrointestinal bleeding). Another important reason to use aspirin as initial therapy is the relative low cost of aspirin, which can lead to better long-term adherence in medication use. Further, for ischemic stroke patients with the complication of hemorrhage at any sites, the choice of drug for secondary prevention of stroke is clopidogrel, instead of aspirin-containing agents.
List of Tables
Table 1 Final stroke diagnosis………………………………21
Table 2 TOAST subtypes of ischemic stroke…………22
Table 3 Risk source of emboli………………………………24
Table 4 Modified Rankin Scale and National Institutes of Health Stroke Scale...25
Table 5 Risk factors and complication………………………26
Table 6 Follow-up………………………………………………27
Table 7 Baseline characteristics……...………………34
Table 8 Hazard ratios for recurrent stroke……………41
Table 9 Hazard ratios for death………………………………41
Table 10 Hazard ratios for recurrent stroke in five TOAST subtypes
(A, large-artery atherosclerosis; B, cardioembolism; C, small-vessel occlusion; D, stroke of other determined etiology; E, stroke of undetermined etiology)…………………………………………………50
Table 11 Hazard ratios for recurrent stroke in history of atrial fibrillation……….52
Table 12 Hazard ratios for recurrent stroke in upper gastrointestinal bleeding…..52
Table 13 Hazard ratios for death in five TOAST subtypes
(A, large-artery atherosclerosis; B, cardioembolism; C, small-vessel occlusion; D, stroke of other determined etiology; E, stroke of undetermined etiology)…………………………………………………57
Table 14 Hazard ratios for death in history of atrial fibrillation………………….59
Table 15 Hazard ratios for death in upper gastrointestinal bleeding……………...59


List of Figures
Figure 1 Study design…………………………………………4
Figure 2 Platelet activation by thromboxane A2…………12
Figure 3 Platelet activation by adenosine diphosphate…13
Figure 4 Flow chart of patient selection…………………33
Figure 5 Kaplan-Meier estimates of the cumulative probability of primary outcomes (A, recurrent stroke; B, death)……………………………...42
Figure 6 Adjusted time-to-event curves of cumulative risk of the primary outcomes (A, recurrent stroke; B, death).………………………………44

Text
Chapter 1 Preface
1.1 Rationale……………………………………………………………..1
1.2 Taiwan Stroke Registry…………………………...2
1.3 Research Goals………………………………………2
Chapter 2 Introduction
2.1 Stroke
2.1.1 Epidemiology………………………………………………5
2.1.2 Types of Stroke…………………………………………5
2.1.3 Definition of Ischemic Stroke and Transient Ischemic Attack
2.1.3.a Definition of Ischemic Stroke…………………6
2.1.3.b Definition of Transient Ischemic Attack……6
2.1.4 Trial of Org 10172 in Acute Stroke Treatment for Subtypes of Ischemic Stroke…………………………7
2.1.5 Clinical Presentation…………………………………7
2.1.6 Risk Factors of Ischemic Stroke…………………8
2.2 Recurrent Stroke……………………………………………8
2.3 Guidelines for the Prevention of Recurrent Stroke……9
2.4 Drug Information of Antiplatelet Agents
2.4.1 Aspirin……………………………………………………………...10
2.4.2 The Combination of Low Dose Aspirin plus Dipyridamole……….10
2.4.3 Clopidogrel…………………………………………………………11
2.5 Clinical Trials of Antiplatelet Therapy for Ischemic Stroke
2.5.1 Previous Clinical Trials..………………………………14
2.5.2 Recent Clinical Trial....……………………………16
2.6 New Study Direction…………………………………………16
Chapter 3 Methods
3.1 Databank
3.1.1 Taiwan Stroke Registry……………………………………17
3.1.2 Participating Hospitals…………………………………17
3.1.3 Participating Specialists……………………18
3.1.4 The Admission Criteria for Taiwan Stroke Registry19
3.1.5 Patient Information of Taiwan Stroke Registry……20
3.2 Patients Selection in the Present Study………………20
3.3 Data Retrieval and Variable Definition…………………20
3.4 Outcomes Events
3.4.1 Primary outcomes…………………………………………28
3.4.2 Subgroup Analyses...………………………………………28
3.5 Statistical Analysis
3.5.1 Baseline Characteristics…………………………………28
3.5.2 Survival Analysis for the Primary Outcomes and Subgroup Analyses...………………………………………………28
3.6 Statistical Software…………………………………29
Chapter 4 Results
4.1 Baseline Characteristics of the Three Treatment Groups……...………..30
4.2 Primary outcomes
4.2.1 Recurrent Stroke after the Onset of Ischemic Stroke or TIA
4.2.1.a One-Month Period……………………………………37
4.2.1.b Three-Month Period…………………………………37
4.2.1.c Six-Month Period……………………………………37
4.2.1.d Cumulative Probability of Recurrent Stroke Within Six Months…………………………………………………………...38
4.2.1 Death after the Onset of Ischemic Stroke or TIA
4.2.1.a One-Month Period……………………………………38
4.2.1.b Three-Month Period…………………………………39
4.2.1.c Six-Month Period……………………………………39
4.2.1.d Cumulative Probability of Death Within Six Months…………..40
4.3 Subgroup Analyses of Recurrent Stroke
4.3.1 Trial of Org 10172 in Acute Stroke Treatment (TOAST) Subtypes
4.3.1.a Large-Artery Atherosclerosis………………………46
4.3.1.b Small-Vessel Occlusion…………………………………46
4.3.1.c Cardioembolism……………………………………………47
4.3.1.d Stroke of Other Determined Etiology…………………47
4.3.1.e Stroke of Undetermined Etiology………………………48
4.3.2 History of Atrial Fibrillation………………………48
4.3.3 Upper Gastrointestinal Bleeding………………………49
4.4 Subgroup Analyses of Death
4.4.1 Trial of Org 10172 in Acute Stroke Treatment (TOAST) Subtypes
4.4.1.a Large-Artery Atherosclerosis…………………………53
4.4.1.b Small-Vessel Occlusion…………………………………53
4.4.1.c Cardioembolism…………………………………………54
4.4.1.d Stroke of Other Determined Etiology………………54
4.4.1.e Stroke of Undetermined Etiology…………55
4.4.2 History of Atrial Fibrillation…………………………55
4.4.3 Upper Gastrointestinal Bleeding………………………56
Chapter 5 Discussion
5.1 The Briefing of New Discovery……………………………60
5.2 Baseline Characteristics of the Three Treatment Groups……………….61
5.3 Primary Outcomes
5.3.1 Recurrent Stroke after the Onset of Ischemic Stroke or TIA……….64
5.3.2 Death after the Onset of Ischemic Stroke or TIA…69
5.4 Subgroup Analyses
5.4.1 Trial of Org 10172 in Acute Stroke Treatment (TOAST) Subtypes..70
5.4.2 History of Atrial Fibrillation………………………72
5.4.3 Upper Gastrointestinal Bleeding………………………74
5.5 Limitations…………………………………………………………75
Chapter 6 Concluding Remarks
6.1 Conclusion………………………………………………77
References…..……………………………………………………78
References
Adams Jr HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL and Marsh Iii EE (1993) Classification of subtype of acute ischemic stroke: Definitions for use in a multicenter clinical trial. Stroke 24:35-41.
Adams RJ, Albers G, Alberts MJ, Benavente O, Furie K, Goldstein LB, Gorelick P, Halperin J, Harbaugh R, Johnston SC, Katzan I, Kelly-Hayes M, Kenton EJ, Marks M, Sacco RL, Schwamm LH, American Heart A and American Stroke A (2008) Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke 39:1647-1652.
Albers GW (2000) Choice of endpoints in antiplatelet trials. Which outcomes are most relevant to stroke patients? Neurology 54:1022-1028.
Albers GW, Amarenco P, Easton JD, Sacco RL and Teal P (2008) Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 133:630S-669S.
Albers GW, Caplan LR, Easton JD, Fayad PB, Mohr JP, Saver JL and Sherman DG (2002) Transient ischemic attack - Proposal for a new definition. New England Journal of Medicine 347:1713-1716.
Algra A and Van Gijn J (1996) Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia. Journal of Neurology Neurosurgery and Psychiatry 60:197-199.
Appelros P, Nydevik I and Viitanen M (2003) Poor outcome after first-ever stroke: Predictors for death, dependency, and recurrent stroke within the first year. Stroke 34:122-126.
Ariesen MJ, Algra A and Kappelle LJ (2006) Antiplatelet drugs in the secondary prevention after stroke: Differential efficacy in large versus small vessel disease? A subgroup analysis from ESPS-2. Stroke 37:134-138.
Armstrong, AW and Golan, DE (2005) Pharmacology of Hemostasis and Thrombosis in Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy, Second Edition, Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia, P.335-356.
Badjatia N and Rosand J (2005) Intracerebral hemorrhage. Neurologist 11:311-324.
Baigent C, Sudlow C, Collins R and Peto R (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. British Medical Journal 324:71-86.
Bhatt DL, Flather MD, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Fabry-Ribaudo L, Hu T, Topol EJ and Fox KAA (2007) Patients With Prior Myocardial Infarction, Stroke, or Symptomatic Peripheral Arterial Disease in the CHARISMA Trial. Journal of the American College of Cardiology 49:1982-1988.
Bhatt DL, Fox KAA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J and Topol EJ (2006) Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. New England Journal of Medicine 354:1706-1717.
Brott T, Adams Jr HP, Olinger CP, Marler JR, Barsan WG, Biller J, Spilker J, Holleran R, Eberle R, Hertzberg V, Rorick M, Moomaw CJ and Walker M (1989) Measurements of acute cerebral infarction: A clinical examination scale. Stroke 20:864-870.
Chen ZM (1997) CAST: Randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet 349:1641-1649.
Chimowitz MI, Lynn MJ, Howlett-Smith H, Stern BJ, Hertzberg VS, Frankel MR, Levine SR, Chaturvedi S, Kasner SE, Benesch CG, Sila CA, Jovin TG and Romano JG (2005) Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. New England Journal of Medicine 352:1305-1316.
Connolly SJ, Pogue J, Chrolavicius S, Hart R, Pfeffer M, Hohnloser S and Yusuf S (2009) Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation. N Engl J Med 360:2066-2078.
Derendorf H, VanderMaelen CP, Brickl RS, MacGregor TR and Eisert W (2005) Dipyridamole bioavailability in subjects with reduced gastric acidity. Journal of Clinical Pharmacology 45:845-850.
Diener HC, Cunha L, Forbes C, Sivenius J, Smets P and Lowenthal A (1996) European stroke prevention study 2 (ESPS-2). Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. Journal of the Neurological Sciences 143:1-13.
Diener PHC, Bogousslavsky PJ, Brass PLM, Cimminiello PC, Csiba PL, Kaste PM, Leys PD, Matias-Guiu PJ and Rupprecht PHJ (2004) Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): Randomised, double-blind, placebo-controlled trial. Lancet 364:331-337.
Dong HS, Phil HL and Oh YB (2005) Mechanisms of recurrence in subtypes of ischemic stroke: A hospital-based follow-up study. Archives of Neurology 62:1232-1237.
Easton JD (1998) Erratum: Benefit of clopidogrel in patients with evidence of cerebrovascular disease. Neurology 51:332.
Eisert WG (2001) Near-field amplification of antithrombotic effects of dipyridamole through vessel wall cells. Neurology 57:S20-S23
Fagan SC and Hess DC (2008) Stroke in Pharmacotherapy: A Pathophysiologic Approach, Seventh Edition, McGraw-Hill Medical, New York, P.373-384.
Gent M (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348:1329-1339.
Goldstein LB, Adams R, Alberts MJ, Appel LJ, Brass LM, Bushnell CD, Culebras A, DeGraba TJ, Gorelick PB, Guyton JR, Hart RG, Howard G, Kelly-Hayes M, Nixon JV and Sacco RL (2006) Primary prevention of ischemic stroke. A guideline from the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council. Stroke 37:1583-1633.
Grau AJ, Weimar C, Buggle F, Heinrich A, Goertler M, Neumaier S, Glahn J, Brandt T, Hacke W and Diener HC (2001) Risk factors, outcome, and treatment in subtypes of ischemic stroke: The German stroke data bank. Stroke 32:2559-2566.
Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ and Algra A (2006) Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 367:1665-1673.
Helgason CM and Wolf PA (1997) American Heart Association Prevention Conference IV: Prevention and Rehabilitation of Stroke: Executive summary. Circulation 96:701-707.
Hu HH, Chu FL, Chiang BN, Lan CF, Sheng WY, Lo YK, Wong WJ and Luk YO (1989) Prevalence of stroke in Taiwan. Stroke 20:858-863.
Jeng JS, Lee TK, Chang YC, Huang ZS, Ng SK, Chen RC and Yip PK (1998) Subtypes and case-fatality rates of stroke: A hospital-based stroke registry in Taiwan (SCAN-IV). Journal of the Neurological Sciences 156:220-226.
Johnston SC, Gress DR, Browner WS and Sidney S (2000) Short-term prognosis after emergency department diagnosis of TIA. Journal of the American Medical Association 284:2901-2906.
Juvela S and Kase CS (2006) Advances in intracerebral hemorrhage management. Stroke 37:301-304.
Kitamura A, Nakagawa Y, Sato M, Iso H, Sato S, Imano H, Kiyama M, Okada T, Okada H, Iida M and Shimamoto T (2006) Proportions of stroke subtypes among men and women > or = 40 years of age in an urban Japanese city in 1992, 1997, and 2002. Stroke 37:1374-1378.
Knapp M, King D, Pugner K and Lapuerta P (2004) Non-adherence to antipsychotic medication regimens: Associations with resource use and costs. British Journal of Psychiatry 184:509-516.
Kolominsky-Rabas PL, Weber M, Gefeller O, Neundoerfer B and Heuschmann PU (2001) Epidemiology of ischemic stroke subtypes according to TOAST criteria: Incidence, recurrence, and long-term survival in ischemic stroke subtypes: A population-based study. Stroke 32:2735-2740.
Liao JK (2007) Secondary prevention of stroke and transient ischemic attack: Is more platelet inhibition the answer? Circulation 115:1615-1621.
Lovett JK, Coull AJ and Rothwell PM (2004) Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies. Neurology 62:569-573.
Mohr JP, Thompson JLP, Lazar RM, Levin B, Sacco RL, Furie KL, Kistler JP, Albers GW, Pettigrew LC, Adams Jr HP, Jackson CM and Pullicino P (2001) A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. New England Journal of Medicine 345:1444-1451.
Ohira T, Shahar E, Chambless LE, Rosamond WD, Mosley TH and Folsom AR (2006) Risk factors for ischemic stroke subtypes: The atherosclerosis risk in communities study. Stroke 37:2493-2498.
Petty GW, Brown Jr RD, Whisnant JP, Sicks JD, O''Fallon WM and Wiebers DO (1999) Ischemic stroke subtypes: A population-based study of incidence and risk factors. Stroke 30:2513-2516.
Petty GW, Brown Jr RD, Whisnant JP, Sicks JD, O''Fallon WM and Wiebers DO (2000) Ischemic stroke subtypes: A population-based study of functional outcome, survival, and recurrence. Stroke 31:1062-1068.
Piette JD, Heisler M and Wagner TH (2004) Problems Paying Out-of-Pocket Medication Costs among Older Adults with Diabetes. Diabetes Care 27:384-391.
Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, Yusuf S and Connolly SJ (2006) Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 367:1903-1912.
Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, Hailpern SM, Ho M, Howard V, Kissela B, Kittner S, Lloyd-Jones D, McDermott M, Meigs J, Moy C, Nichol G, O''Donnell C, Roger V, Sorlie P, Steinberger J, Thom T, Wilson M and Hong Y (2008) Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117:e25-e146.
Rothwell PM and Warlow CP (2005) Timing of TIAs preceding stroke: Time window for prevention is very short. Neurology 64:817-820.
Sacco RL, Adams R, Albers G, Alberts MJ, Benavente O, Furie K, Goldstein LB, Gorelick P, Halperin J, Harbaugh R, Johnston SC, Katzan I, Kelly-Hayes M, Kenton EJ, Marks M, Schwamm LH and Tomsick T (2006) Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: A statement for healthcare professionals from the American Heart Association/American Stroke Association council on stroke - Co-sponsored by the council on cardiovascular radiology and intervention. The American Academy of Neurology affirms the value of this guideline. Stroke 37:577-617.
Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BPL, Chen ST, Cunha L, Dahlo?f B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, Vander Maelen C, Voigt T, Weber M and Yoon BW (2008) Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. New England Journal of Medicine 359:1238-1251.
Sandercock PAG (1997) The International Stroke Trial (IST): A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke. Lancet 349:1569-1581.
Sarasin FP, Gaspoz JM and Bounameaux H (2000) Cost-effectiveness of new antiplatelet regimens used as secondary prevention of stroke or transient ischemic attack. Archives of Internal Medicine 160:2773-2778.
Savi P, Heilmann E, Nurden P, Laplace MC, Bihour C, Kieffer G, Nurden AT and Herbert JM (1996) Clopidogrel: An antithrombotic drug acting on the ADP-dependent activation pathway of human platelets. Clinical and Applied Thrombosis/Hemostasis 2:35-42.
Savi P, Laplace MC, Maffrand JP and Herbert JM (1994) Binding of [3H]-2-methylthio ADP to rat platelets - Effect of clopidogrel and ticlopidine. Journal of Pharmacology and Experimental Therapeutics 269:772-777.
Schulz UGR and Rothwell PM (2003) Differences in vascular risk factors between etiological subtypes of ischemic stroke: Importance of population-based studies. Stroke 34:2050-2059.
Steg G, Bhatt DL, Wilson PWF, D''Agostino Sr R, Ohman EM, Rother J, Liau CS, Hirsch AT, Mas JL, Ikeda Y, Pencina MJ and Goto S (2007) One-year cardiovascular event rates in outpatients with atherothrombosis. Journal of the American Medical Association 297:1197-1206.
Theis JGW, Deichsel G and Marshall S (1999) Rapid development of tolerance to dipyridamole-associated headaches. British Journal of Clinical Pharmacology 48:750-755.
Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, Zheng ZJ, Flegal K, O''Donnell C, Kittner S, Lloyd-Jones D, Goff Jr DC and Hong Y (2006) Heart disease and stroke statistics - 2006 Update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 113:e85-e151.
Tseng CH, Chong CK, Sheu JJ, Wu TH and Tseng CP (2005) Prevalence and risk factors for stroke in Type 2 diabetic patients in Taiwan: A cross-sectional survey of a national sample by telephone interview. Diabetic Medicine 22:477-482.
Uchino K, Risser JMH, Smith MA and Morgenstern LB (2004) Ischemic stroke subtypes among Mexican Americans and non-Hispanic whites: The BASIC project. Neurology 63:574-576.
Van Latum JC, Vermeulen PC, Den Ouden A, Mast B, Koudstaal PJ, Bogousslavsky J, Boysen G, Bornstein N, Candelise L, Dahl T, Dehaene I, Ferro J, Van Gijn J, Gustafsson C, Hedenus M, Hijdra A, Kramer G, Lodder J and Mas JL (1993) Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 342:1255-1262.
Van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJA and Van Gijn J (1988) Interobserver agreement for the assessment of handicap in stroke patients. Stroke 19:604-607.
Vane JR and Botting RM (2003) The mechanism of action of aspirin. Thrombosis Research 110:255-258.
Warlow (1991) The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: Final results. Journal of Neurology Neurosurgery and Psychiatry 54:1044-1054.
Warlow C (1992) Secondary prevention of stroke. Lancet 339:724-727.
Wolf PA (2003) Fifty years at Framingham: contributions to stroke epidemiology. Advances in neurology 92:165-172.
Yip PK, Jeng JS, Lee TK, Chang YC, Huang ZS, Ng SK and Chen RC (1997) Subtypes of ischemic stroke: A hospital-based stroke registry in Taiwan (SCAN-IV). Stroke 28:2507-2512.
中華民國行政院衛生署 (2008) 97年死因統計結果分析 Available at: http://www.doh.gov.tw/
台灣腦中風學會 (2009) Available at: http://www.stroke.org.tw/
QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top